112 related articles for article (PubMed ID: 1827100)
1. Individual and combined activities of clarithromycin and its 14-hydroxy metabolite in a murine model of Haemophilus influenzae infection.
Vallée E; Azoulay-Dupuis E; Swanson R; Bergogne-Bérézin E; Pocidalo JJ
J Antimicrob Chemother; 1991 Feb; 27 Suppl A():31-41. PubMed ID: 1827100
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans.
Hardy DJ; Swanson RN; Rode RA; Marsh K; Shipkowitz NL; Clement JJ
Antimicrob Agents Chemother; 1990 Jul; 34(7):1407-13. PubMed ID: 2143642
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of clarithromycin and its 14-hydroxy-metabolite against 203 strains of Haemophilus influenzae.
Bergeron MG; Bernier M; L'Ecuyer J
Infection; 1992; 20(3):164-7. PubMed ID: 1386590
[TBL] [Abstract][Full Text] [Related]
4. The activity of clarithromycin and its 14-hydroxy metabolite against Haemophilus influenzae, determined by in-vitro and serum bactericidal tests.
Dabernat H; Delmas C; Seguy M; Fourtillan JB; Girault J; Lareng MB
J Antimicrob Chemother; 1991 Feb; 27 Suppl A():19-30. PubMed ID: 1827099
[TBL] [Abstract][Full Text] [Related]
5. Protective efficacy of clarithromycin and its 14-hydroxy metabolite against Haemophilus influenzae in a murine septicaemia model.
Chen HY; Maskell JP; Powell M
J Antimicrob Chemother; 1992 May; 29(5):602-3. PubMed ID: 1385590
[No Abstract] [Full Text] [Related]
6. Bactericidal activity of clarithromycin and its 14-hydroxy metabolite against Haemophilus influenzae and streptococcal pathogens.
Gu JW; Scully BE; Neu HC
J Clin Pharmacol; 1991 Dec; 31(12):1146-50. PubMed ID: 1837032
[TBL] [Abstract][Full Text] [Related]
7. In-vitro activity of clarithromycin combined with its 14-hydroxy metabolite A-62671 against Haemophilus influenzae.
Olsson-Liljequist B; Hoffman BM
J Antimicrob Chemother; 1991 Feb; 27 Suppl A():11-7. PubMed ID: 1827097
[TBL] [Abstract][Full Text] [Related]
8. Activity and local delivery of azithromycin in a mouse model of Haemophilus influenzae lung infection.
Vallée E; Azoulay-Dupuis E; Pocidalo JJ; Bergogne-Bérézin E
Antimicrob Agents Chemother; 1992 Jul; 36(7):1412-7. PubMed ID: 1324644
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility of Haemophilus influenzae to clarithromycin alone and in combination with its 14-hydroxy metabolite.
Barry AL; Fuchs PC; Pfaller MA
Eur J Clin Microbiol Infect Dis; 1991 Dec; 10(12):1080-1. PubMed ID: 1839381
[No Abstract] [Full Text] [Related]
10. In-vitro cidal activity of clarithromycin and its 14-hydroxy metabolite (A-62671) against Haemophilus influenzae.
Powell M; Chen HY; Weinhardt B; Williams JD
J Antimicrob Chemother; 1991 May; 27(5):694-6. PubMed ID: 1832146
[No Abstract] [Full Text] [Related]
11. The in-vitro and disc susceptibility testing of clarithromycin and its 14-hydroxy metabolite.
Logan MN; Ashby JP; Andrews JM; Wise R
J Antimicrob Chemother; 1991 Feb; 27(2):161-70. PubMed ID: 1829073
[TBL] [Abstract][Full Text] [Related]
12. Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential.
Peters DH; Clissold SP
Drugs; 1992 Jul; 44(1):117-64. PubMed ID: 1379907
[TBL] [Abstract][Full Text] [Related]
13. Activity of clarithromycin and its principal human metabolite against Haemophilus influenzae.
Jorgensen JH; Maher LA; Howell AW
Antimicrob Agents Chemother; 1991 Jul; 35(7):1524-6. PubMed ID: 1834012
[TBL] [Abstract][Full Text] [Related]
14. Clarithromycin in vitro activity enhanced by its major metabolite, 14-hydroxyclarithromycin.
Hoover WW; Barrett MS; Jones RN
Diagn Microbiol Infect Dis; 1992; 15(3):259-66. PubMed ID: 1533827
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the in-vitro activity of clarithromycin, a new macrolide antibiotic, with erythromycin and other oral agents.
King A; Phillips I
J Hosp Infect; 1991 Sep; 19 Suppl A():3-9. PubMed ID: 1684981
[TBL] [Abstract][Full Text] [Related]
16. Individual efficacy of clarithromycin (A-56268) and its major human metabolite 14-hydroxy clarithromycin (A-62671) in experimental pneumococcal pneumonia in the mouse.
Bédos JP; Azoulay-Dupuis E; Vallée E; Veber B; Pocidalo JJ
J Antimicrob Chemother; 1992 Jun; 29(6):677-85. PubMed ID: 1387132
[TBL] [Abstract][Full Text] [Related]
17. Clarithromycin, a unique macrolide. A pharmacokinetic, microbiological, and clinical overview.
Hardy DJ; Guay DR; Jones RN
Diagn Microbiol Infect Dis; 1992 Jan; 15(1):39-53. PubMed ID: 1530914
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of antimicrobial activities of clarithromycin and 14-hydroxyclarithromycin against three strains of Haemophilus influenzae by using an in vitro pharmacodynamic model.
Walker KJ; Larsson AJ; Zabinski RA; Rotschafer JC
Antimicrob Agents Chemother; 1994 Sep; 38(9):2003-7. PubMed ID: 7811010
[TBL] [Abstract][Full Text] [Related]
19. Activities of two novel macrolides, GW 773546 and GW 708408, compared with those of telithromycin, erythromycin, azithromycin, and clarithromycin against Haemophilus influenzae.
Kosowska K; Credito K; Pankuch GA; Hoellman D; Lin G; Clark C; Dewasse B; McGhee P; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2004 Nov; 48(11):4113-9. PubMed ID: 15504829
[TBL] [Abstract][Full Text] [Related]
20. In vivo efficacy of telithromycin (HMR3647) against Streptococcus pneumoniae and Haemophilus influenzae.
Okamoto H; Miyazaki S; Tateda K; Ishii Y; Yamaguchi K
Antimicrob Agents Chemother; 2001 Nov; 45(11):3250-2. PubMed ID: 11600393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
